ESTRO 2025 - Abstract Book

S1251

Clinical – Lower GI

ESTRO 2025

Results: The baseline characteristics were same between two groups (Figure 1).

The reason for not undergoing surgery was patients' refusal in 12 (38.7%), emergence of new metastasis at re staging/laparotomy in 5 (16.1%), medical inoperability in 4 (13%), unresectabillity in 8 (25.8%), dying after or during CRT in 1 (3.2%) and unknown 1 (3.2%). The median OS was 22 (95%CI: 14-30) vs. 123 (95%CI:61-184) months in the non-surgical and surgical groups, respectively (P<0.001). The 5-year OS was 16% (95%CI: 2-30) vs. 68% (95%CI: 54-82) in the non-surgical and surgical groups, respectively. Patients who refused surgery after CRT although had the best median OS (50 months [95%CI: 31-68]) and 5-year OS (42% [95%CI: 15-69]) in the non-surgical group, but this still was significantly inferior to surgical group (Figure 2).